TY - JOUR
T1 - Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment
AU - Dhimolea, Eugen
AU - de Matos Simoes, Ricardo
AU - Kansara, Dhvanir
AU - Weng, Xiang
AU - Sharma, Shruti
AU - Awate, Pallavi
AU - Liu, Zhiyi
AU - Gao, Dong
AU - Mitsiades, Nicholas
AU - Schwab, Joseph H.
AU - Chen, Yu
AU - Jeselsohn, Rinath
AU - Culhane, Aedín C.
AU - Brown, Myles
AU - Georgakoudi, Irene
AU - Mitsiades, Constantine S.
N1 - Funding Information:
We thank Zach Herbert and the members of DFCI Molecular Biology Core Facilities for the transcriptional analyses. This study was supported by the Breast Cancer Alliance Young Investigator Award (to E. Dhimolea and C.S. Mitsiades), Claudia Adams Barr Program for Innovative Cancer Research (to E. Dhimolea and C.S. Mitsiades), Hellenic Women’s Club (to E. Dhimolea and C.S. Mitsiades), Terri Brodeur Breast Cancer Foundation Grant (to E. Dhimolea), Avon Foundation Breast Cancer Research Program (to E. Dhimolea and C.S. Mitsiades), Elsa U. Pardee Foundation Grant (to E. Dhimolea and C.S. Mitsiades), Department of Defense grants W81XWH-15-1-0013 (to A.C. Culhane) and W81XWH-15-1-0012 (to C.S. Mitsiades), National Cancer Institute Grant U54-CA233223 (to N. Mitsiades), Leukemia and Lymphoma Society Scholar Award (to C.S. Mitsiades), Ludwig Center at Harvard (to C.S. Mitsiades), and National Cancer Institute Grant U54-CA233223 (to N. Mitsiades). Raw CRISPR and RNA-seq sequencing data was processed on the Orchestra High Performance Computer Cluster at Harvard Medical School (grant NCRR 1S10RR028832-01, http://rc. hms.harvard.edu).
Funding Information:
We thank Zach Herbert and the members of DFCI Molecular Biology Core Facilities for the transcriptional analyses. This study was supported by the Breast Cancer Alliance Young Investigator Award (to E. Dhimolea and C.S. Mitsiades), Claudia Adams Barr Program for Innovative Cancer Research (to E. Dhimolea and
Funding Information:
E. Dhimolea reports grants from Breast Cancer Alliance (Young Investigator Award), Claudia Adams Barr Program for Innovative Cancer Research Award, Hellenic Women’s Club, Terri Brodeur Breast Cancer Foundation, Avon Foundation Breast Cancer Research Program, and Elsa U. Pardee Foundation during the conduct of the study. N. Mitsiades reports grants from NCI Grant (U54-CA233223) during the conduct of the study. Y. Chen reports personal fees from Oric Pharmaceuticals outside the submitted work. R. Jeselsohn reports grants from Lilly and Pfizer and personal fees from Carrick and Luminex outside the submitted work. M. Brown reports grants from Novartis and personal fees from Kronos Bio, H3 Biomedicine, and GV20 Therapeutics outside the submitted work. I. Georgakoudi reports a patent for System and Method for Assessing Cellular Metabolic Activity pending. C.S. Mitsiades reports grants from Department of Defense (grant W81XWH-15-1-0012), Breast Cancer Alliance Young Investigator Award, Claudia Adams Barr Program for Innovative Cancer Research, Hellenic Women’s Club, Terri Brodeur Breast Cancer Foundation, Avon Foundation Breast Cancer Research Program, Leukemia and Lymphoma Society Scholar Award, Ludwig Center at Harvard, and Elsa U. Pardee Foundation during the conduct of the study. C.S. Mitsiades also reports relationships with Takeda (employment of a family member), Fate Therapeutics (consultant/ honoraria), Ionis Pharmaceuticals (consultant/honoraria), and FIMECS (consultant/ honoraria), grants from Sanofi (research funding), Arch Oncology (research funding), EMD Serono/Merck KGA (research funding), Abbvie (research funding), Karyopharm (research funding), Janssen/Johnson & Johnson (research funding), TEVA (research funding), and Novartis (research funding) outside the submitted work; and has been an inventor/coinventor over the last 15 years in several patent applications pertinent to the broader theme of resistance of different types of cancers to various therapeutics, including applications that have involved studies of tumor cells cocultured with nonmalignant cells of their microenvironment in conventional 2D culture or 3D systems. No disclosures were reported by the other authors.
Publisher Copyright:
©2020 American Association for Cancer Research.
PY - 2021/1/15
Y1 - 2021/1/15
N2 - Although hormonal therapy (HT) inhibits the growth of hormone receptor–positive (HRþ) breast and prostate cancers, HT resistance frequently develops within the complex metastatic microenvironment of the host organ (often the bone), a setting poorly recapitulated in 2D culture systems. To address this limitation, we cultured HRþ breast cancer and prostate cancer spheroids and patient-derived organoids in 3D extracellular matrices (ECM) alone or together with bone marrow stromal cells (BMSC). In 3D monocultures, antiestrogens and antiandrogens induced anoikis by abrogating anchorage-independent growth of HRþ cancer cells but exhibited only modest effects against tumor cells residing in the ECM niche. In contrast, BMSC induced hormone-independent growth of breast cancer and prostate cancer spheroids and restored lumen filling in the presence of HR-targeting agents. Molecular and functional characterization of BMSC-induced hormone independence and HT resistance in anchorage-independent cells revealed distinct context-dependent mechanisms. Cocultures of ZR75-1 and LNCaP with BMSCs exhibited paracrine IL6-induced HT resistance via attenuation of HR protein expression, which was reversed by inhibition of IL6 or JAK signaling. Paracrine IL6/JAK/STAT3-mediated HT resistance was confirmed in patient-derived organoids cocultured with BMSCs. Distinctly, MCF7 and T47D spheroids retained ER protein expression in cocultures but acquired redundant compensatory signals enabling anchorage independence via ERK and PI3K bypass cascades activated in a non–IL6-dependent manner. Collectively, these data characterize the pleiotropic hormone-independent mechanisms underlying acquisition and restoration of anchorage-independent growth in HRþ tumors. Combined analysis of tumor and microenvironmental biomarkers in metastatic biopsies of HT-resistant patients can help refine treatment approaches. Significance: This study uncovers a previously underappreciated dependency of tumor cells on HR signaling for anchorage-independent growth and highlights how the metastatic microenvironment restores this malignant property of cancer cells during hormone therapy.
AB - Although hormonal therapy (HT) inhibits the growth of hormone receptor–positive (HRþ) breast and prostate cancers, HT resistance frequently develops within the complex metastatic microenvironment of the host organ (often the bone), a setting poorly recapitulated in 2D culture systems. To address this limitation, we cultured HRþ breast cancer and prostate cancer spheroids and patient-derived organoids in 3D extracellular matrices (ECM) alone or together with bone marrow stromal cells (BMSC). In 3D monocultures, antiestrogens and antiandrogens induced anoikis by abrogating anchorage-independent growth of HRþ cancer cells but exhibited only modest effects against tumor cells residing in the ECM niche. In contrast, BMSC induced hormone-independent growth of breast cancer and prostate cancer spheroids and restored lumen filling in the presence of HR-targeting agents. Molecular and functional characterization of BMSC-induced hormone independence and HT resistance in anchorage-independent cells revealed distinct context-dependent mechanisms. Cocultures of ZR75-1 and LNCaP with BMSCs exhibited paracrine IL6-induced HT resistance via attenuation of HR protein expression, which was reversed by inhibition of IL6 or JAK signaling. Paracrine IL6/JAK/STAT3-mediated HT resistance was confirmed in patient-derived organoids cocultured with BMSCs. Distinctly, MCF7 and T47D spheroids retained ER protein expression in cocultures but acquired redundant compensatory signals enabling anchorage independence via ERK and PI3K bypass cascades activated in a non–IL6-dependent manner. Collectively, these data characterize the pleiotropic hormone-independent mechanisms underlying acquisition and restoration of anchorage-independent growth in HRþ tumors. Combined analysis of tumor and microenvironmental biomarkers in metastatic biopsies of HT-resistant patients can help refine treatment approaches. Significance: This study uncovers a previously underappreciated dependency of tumor cells on HR signaling for anchorage-independent growth and highlights how the metastatic microenvironment restores this malignant property of cancer cells during hormone therapy.
UR - http://www.scopus.com/inward/record.url?scp=85099680768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099680768&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-0571
DO - 10.1158/0008-5472.CAN-20-0571
M3 - Article
C2 - 32859606
AN - SCOPUS:85099680768
SN - 0008-5472
VL - 81
SP - 371
EP - 383
JO - Cancer research
JF - Cancer research
IS - 2
ER -